The association of tidal EFL with exercise performance, exacerbations, and death in COPD

Bernt Boegvald Aarli¹,² Peter MA Calverley³ Robert L Jensen⁴ Raffaele Dellacà⁵ Tomas ML Eagan¹,² Per S Bakke¹ Jon A Hardie¹

¹Department of Clinical Science, University of Bergen; ²Department of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway; ³Clinical Science Centre, University Hospital Aintree, Liverpool, UK; ⁴LDS Hospital, Pulmonary Division, Salt Lake City, UT, USA; ⁵TBM-Lab, Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano University, Milano, Italy

Background: Tidal expiratory flow limitation (EFL) is frequently found in patients with COPD and can be detected by forced oscillations when within-breath reactance of a single-breath is \( \geq 0.28 \text{kPa L}^{-1} \text{s}^{-1} \). The present study explored the association of within-breath reactance measured over multiple breaths and EFL with 6-minute walk distance (6MWD), exacerbations, and mortality.

Methods: In 425 patients, spirometry and forced oscillation technique measurements were obtained on eight occasions over 3 years. 6MWD was assessed at baseline and at the 3-year visit. Respiratory symptoms, exacerbations, and hospitalizations were recorded. A total of 5-year mortality statistics were retrieved retrospectively. We grouped patients according to the mean within-breath reactance (\( \Delta X_{rs} \)), measured over several breaths at baseline, calculated as mean inspiratory–mean expiratory reactance over the sampling period. In addition to the established threshold of EFL, an upper limit of normal (ULN) was defined using the 97.5th percentile of \( \Delta X_{rs} \) of the healthy controls in the study; 6MWDs were compared according to \( \Delta X_{rs} \), as normal, \( \geq \) ULN < EFL or \( \geq \) EFL. Annual exacerbation rates were analyzed using a negative binomial model in the three groups, supplemented by time to first exacerbation analysis, and dichotomizing patients at the ULN.

Results: In patients with COPD and baseline \( \Delta X_{rs} \) below the ULN (0.09 kPa L\(^{-1}\) s\(^{-1}\)), 6MWD was stable. 6MWD declined significantly in patients with \( \Delta X_{rs} \geq \) ULN. Worse lung function and more exacerbations were found in patients with COPD with \( \Delta X_{rs} \geq \) ULN, and patients with \( \Delta X_{rs} \geq \) ULN had shorter time to first exacerbation and hospitalization. A significantly higher mortality was found in patients with \( \Delta X_{rs} \geq \) ULN and FEV\(_1\) > 50%.

Conclusion: Patients with baseline \( \Delta X_{rs} \geq \) ULN had a deterioration in exercise performance, more exacerbations, and greater hospitalizations, and, among those with moderate airway obstruction, a higher mortality. \( \Delta X_{rs} \) is a novel independent marker of outcome in COPD.

Keywords: forced oscillation technique, reactance, COPD, exacerbations, 6-minute walk test, mortality

Introduction

COPD is a major cause of morbidity and mortality, leading to an estimated 3.1 million deaths globally in 2012. Although symptoms and exacerbation rate have been added to our assessment system of COPD, spirometry remains an important tool in assessing severity and prognosis in this disease. Changes in the forced expiratory volume in 1 second (FEV\(_1\)) are still the best indicator of disease progression and the risk of dying from COPD. Yet, on an individual level, FEV\(_1\) is an unreliable marker of morbidity, especially in early disease, and there is a need to identify alternative objective tests that can aid in stratifying the risk of further patient deterioration.
Patients who exhibit tidal expiratory flow limitation (EFL\textsubscript{\text{t}}) might be such a subgroup. EFL\textsubscript{\text{t}} occurs when increases in driving pressure fail to increase expiratory flow during resting tidal breathing and is most often seen in patients with severe COPD, \textsuperscript{7,8} although it can occur with only moderate airway obstruction. Previous studies of EFL\textsubscript{\text{t}} in COPD have focused on its association with operating lung volume, exercise tolerance, \textsuperscript{9,10} and its relation to breathlessness.\textsuperscript{11-13} It is not known whether EFL\textsubscript{\text{t}} can provide longer-term prognostic information in COPD.

EFL\textsubscript{\text{t}} can be detected by the forced oscillation technique (FOT).\textsuperscript{14,15} When peripheral airways collapse on expiration, oscillatory pressure signals are prevented from reaching the alveoli. As this happens, the oscillatory compliance is reduced. Consequently, expiratory reactance (\(X_{\text{rs}}\)) becomes more negative than the inspiratory reactance (\(X_{\text{insp}}\)), leading to a within-breath reactance difference (\(\Delta X_{\text{rs}}\)). In the absence of EFL\textsubscript{\text{t}}, reactance measured in inspiration and in expiration is almost identical. The within-breath reactance difference (\(\Delta X_{\text{rs}}\)) cut-off of 0.28 kPa\textsuperscript{-1} has been defined and validated to identify flow-limited breaths.\textsuperscript{14,15} EFL\textsubscript{\text{t}} is not only linked to dyspnea in COPD,\textsuperscript{11,16} but also to COPD exacerbations, where \(\Delta X_{\text{rs}}\) have been found to increase at the onset of COPD exacerbations and decrease when the exacerbation resolves.\textsuperscript{17}

In this study, we used forced oscillation technique to define EFL\textsubscript{\text{t}} in 425 patients with COPD. We hypothesized that the presence of EFL\textsubscript{\text{t}}, assessed by increased mean \(\Delta X_{\text{rs}}\) (\(\Delta X_{\text{rs}}\)), would relate to changes in 6MWD, the risk of COPD exacerbations, and, possibly, mortality. We explored these hypotheses using baseline \(\Delta X_{\text{rs}}\) as a predictor for future events. Patients with COPD with abnormally high \(\Delta X_{\text{rs}}\), both above the upper limit of normal (ULN) and above the established threshold of EFL\textsubscript{\text{t}}, were investigated to determine whether they differed from those without evidence of tidal expiratory flow limitation.

**Methods**

**Study design and patients**

The current data derive from the Bergen cohort of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study,\textsuperscript{18} with additional patients enrolled from our clinical catchment area. Written informed consent was obtained from all study subjects. The study was approved by the regional ethics committee, REK vest (REK 165.08), and performed in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines (ClinicalTrials.gov; No: NCT00292552; www.ClinicalTrials.gov).\textsuperscript{39}

Inclusion criteria for patients with COPD were: age 40–75 years, FEV\textsubscript{1} <80% predicted, FEV\textsubscript{1}/FVC <0.7, and a smoking history of \(\geq 10\) pack-years. Study patients were evaluated every 6 months for 3 years with an additional visit at 3 months after baseline, totaling eight visits. The American Thoracic Society–Division of Lung Disease (ATS-DLD-78) questionnaire and the modified Medical Research Council dyspnea scale score (mMRC) were used to record respiratory symptoms.\textsuperscript{19,20}

Post-bronchodilator spirometry and oscillatory lung mechanics during tidal breathing were performed after inhalation of 0.4 mg salbutamol (GlaxoSmithKline, Ventolin, London, UK) according to American Thoracic Society/European Respiratory Society (ATS/ERS) international standards at each visit using a Jaeger MasterScope CT Impulse Oscillation System (Jaeger, Hoechberg, Germany).\textsuperscript{21,22} Local reference values were used to determine the FEV\textsubscript{1} % predicted.\textsuperscript{23} The FOT measurements were performed with the patient seated, cheeks supported, and wearing a nose clip. We performed three continuous measurements of 30 seconds, totaling 90 seconds of tidal volume breathing. Acceptability of measurements was determined using the ERS 2003 task force recommendations.\textsuperscript{22}

\(\Delta X_{\text{rs}}\) reactance was averaged over the 90-second sample, containing several breaths, and was calculated as follows: \(\Delta X_{\text{rs}} = 0.09 \text{ kPa}\text{·s}\text{·L}^{-1}\). Two cut-offs were investigated: the ULN defined as the 97.5th percentile of healthy controls in the Bergen cohort of the ECLIPSE study (\(\Delta X_{\text{rs}} > 0.09 \text{ kPa}\text{·s}\text{·L}^{-1}\); Figure S1),\textsuperscript{13} and at the established EFL\textsubscript{\text{t}} defining threshold for within-breath reactance, 0.28 kPa\textsuperscript{-1}, derived from single-breath analysis.\textsuperscript{14,15} To illustrate the variability of our multiple-breath measurement, \(\Delta X_{\text{rs}}\) was plotted against time in a subset of the patients defined EFL\textsubscript{\text{t}} at baseline with complete visits (\(N=20\)).

**Study outcomes**

Distance walked during the 6-minute walk test (6MWT) was used to assess exercise performance. The 6MWT was supervised by a trained technician and performed in a 30-m, straight hospital corridor according to agreed standards at baseline and at the end of the study, at the 3-year visit.\textsuperscript{24}

Exacerbations were defined as a worsening of respiratory symptoms over 2 days or more that required systemic corticosteroids or antibiotics, alone or in combination (“moderate exacerbations”), or exacerbations resulting in hospitalization (“severe exacerbations”). Assessment of exacerbations was performed retrospectively by the study physician at the half-yearly visits, over the 3-year study period.

Mortality statistics were retrieved on August 25, 2011, approximately 5 years after the conclusion of the baseline
visit by checking vital status in our local patient file system, which is linked to the Norwegian Causes of Death Registry. The Causes of Death Registry includes deaths of all residents, regardless of whether they die in Norway or abroad, and is assumed to have information on >98% of all deaths.25

**Statistics**

IBM SPSS version 22, Stata 13.1, and R 3.2.3 GUI 1.66 were used for different aspects of statistical analyses. Data are presented as mean ± standard deviation, median (quartiles), mean (95% confidence interval), and absolute count or percentage. Means were compared using independent samples t-tests, paired samples t-tests, or Mann–Whitney U test when appropriate.

Patients were categorized into three groups according to \( \Delta X_{rs} \): normal, ≥ ULN < EFL\(_T\), and ≥ EFL\(_T\) at baseline. We report the change in the 6-minute walk distance in these three groups from baseline to the 3-year visit in notched boxplots. Differences in walking distance between baseline and the end of the study were compared using paired samples t-test, grouping the patients according to the \( \Delta X_{rs} \) and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade.2

The rate of exacerbations in the three groups was analyzed as suggested by Keene et al using a negative binomial regression model, accounting for the yearly variability among test subjects in the exacerbation rate over the 3-year study period, adjusting for FEV\(_1\), age, sex, and a binary classifier identifying frequent exacerbators in the year prior to inclusion.26 Parameter effects of the baseline explanatory variables are reported as annual rate ratios (RRs), 95% confidence interval (CI), and P-values. Moderate and severe exacerbations requiring hospitalization were also investigated on the basis of the occurrence of \( \Delta X_{rs} \) ≥ ULN at baseline by time to first event analysis. Groups were compared using a log-rank test. Results are displayed as 1-minus-survival plots.

Survival analysis was performed with Kaplan–Meier survival analysis, comparing distributions with the log-rank test, grouping patients by the occurrence of \( \Delta X_{rs} \) ≥ ULN at baseline, and by dichotomizing FEV\(_1\) at 50% of that predicted.

**Results**

**Baseline characteristics**

In this population of patients with COPD, 60% were men and had moderate to very severe airway obstruction. Women were, on average, 2 years younger and had lower tobacco exposure (Table S1); 50% of patients with COPD had normal \( \Delta X_{rs} \), 31% were classified as being abnormal with \( \Delta X_{rs} \) ≥ ULN < EFL\(_T\), and 18% had \( \Delta X_{rs} \) above the threshold of EFL\(_T\) (Table 1). From the normal to the abnormal group, lung function worsened with a decline in FEV\(_1\) and FVC, and an increase in body mass index (BMI) and mMRC. This difference was most marked between the normal and EFL\(_T\) group. For IC, we only found a significant difference between the normal and the EFL\(_T\) group.

**Table 1** Baseline characteristics in COPD patients with different levels of \( \Delta X_{rs} \) (N=425)

<table>
<thead>
<tr>
<th>Subject characteristics</th>
<th>Normal (( \Delta X_{rs} &lt; ULN ))</th>
<th>Abnormal (ULN ≥ ( \Delta X_{rs} &lt; EFL_{T} ))</th>
<th>EFL(<em>T) (( \Delta X</em>{rs} &gt; 0.28 \text{ kPa s L}^{-1} ))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects (n)</td>
<td>213 (50%)</td>
<td>134 (32%)</td>
<td>78 (18%)</td>
</tr>
<tr>
<td>Women</td>
<td>40%</td>
<td>36%</td>
<td>49%</td>
</tr>
<tr>
<td>Age (years)</td>
<td>63 (7)</td>
<td>64 (7)</td>
<td>63 (6)</td>
</tr>
<tr>
<td>BMI kg/m(^2)</td>
<td>24 (5)(^{c,d})</td>
<td>26 (5)(^{c,a})</td>
<td>28 (6)(^{c,a})</td>
</tr>
<tr>
<td>Pack-years (years)</td>
<td>40 (24)</td>
<td>43 (22)</td>
<td>39 (22)</td>
</tr>
<tr>
<td>Frequent exacerbators (%)</td>
<td>13%</td>
<td>20%</td>
<td>35%</td>
</tr>
<tr>
<td>mMRC</td>
<td>1.2 (0.2)(^{c,e})</td>
<td>1.8 (0.25, 2)(^{c,a})</td>
<td>2.3 (1, 2)(^{c,a})</td>
</tr>
<tr>
<td>FEV(_1) (L)</td>
<td>1.7 (0.5)(^{c,d})</td>
<td>1.3 (0.5)(^{e})</td>
<td>1.1 (0.4)(^{e})</td>
</tr>
<tr>
<td>FEV(_1) (%)</td>
<td>52 (11)(^{c,d})</td>
<td>42 (12)(^{e})</td>
<td>38 (13)(^{e})</td>
</tr>
<tr>
<td>FVC (L)</td>
<td>3.5 (0.9)(^{c,e})</td>
<td>3.2 (0.8)(^{e})</td>
<td>2.8 (0.9)(^{e})</td>
</tr>
<tr>
<td>IC (L)</td>
<td>2.6 (0.8)(^{e})</td>
<td>2.5 (0.7)</td>
<td>2.3 (0.7)(^{e})</td>
</tr>
<tr>
<td>IC (%)</td>
<td>88 (19)</td>
<td>85 (20)</td>
<td>84 (21)</td>
</tr>
<tr>
<td>6MWD (meters)</td>
<td>455 (102)(^{c,d})</td>
<td>410 (109)(^{c,e})</td>
<td>363 (110)(^{e})</td>
</tr>
<tr>
<td>Estimated exacerbations per year(^{a})</td>
<td>0.7</td>
<td>1.3</td>
<td>1.6</td>
</tr>
<tr>
<td>Deaths(^{a})</td>
<td>25 (12)(^{c,d})</td>
<td>28 (21)(^{e})</td>
<td>18 (23)(^{e})</td>
</tr>
</tbody>
</table>

**Notes:** Data presented as mean ± standard deviation unless otherwise stated. *Estimated exacerbation rate by negative binomial model. *Number of deaths at the 5-year census (%). Significant differences at the 5% level are marked as ‘between normal and abnormal’, ‘between normal and EFL\(_T\)’, and ‘between abnormal and EFL\(_T\)’. Pack-years: packs of 20 cigarettes smoked per day × years as a smoker; Frequent exacerbators: percentage with ≥ 2 exacerbations the year prior to inclusion.

**Abbreviations:** ULN, upper limit of normal 0.09 kPa s L\(^{-1}\); EFL\(_T\), tidal expiratory flow limitation; BMI, body mass index; mMRC, modified Medical Research Council dyspnea scale score – mean (quartiles); FEV\(_1\), forced expiratory volume in 1 second; FEV\(_1\) (%), FEV\(_1\) percentage of predicted; FVC, forced vital capacity; IC, inspiratory capacity; IC (%), IC percentage of predicted; \( \Delta X_{rs} \), difference between mean inspiratory and mean expiratory reactance at 5 Hz over multiple breaths; 6MWD, 6-minute walk distance.
Deaths and dropouts during the 3-year study period

Grouping by GOLD grade produced similar boxplots. GOLD 2 patients remained stable whereas a significant decline was seen in GOLD 3–4 grades (Figure 2D).

A total of 1,289 moderate to severe exacerbations were recorded throughout the study. By negative binomial regression, estimated annual exacerbations rates were 0.7 in patients with normal $\Delta X_{rs}$, 1.3 in patients with COPD with $\Delta X_{rs} \geq ULN$, and 1.6 in patients with $EFL_{r_7}$. Annual exacerbation RR compared to the normal group was 1.28 for ULN patients and 1.30 for $EFL_{r_7}$ patients (Table 3). A time to first exacerbation analysis was performed in patients with COPD with and without evidence of $\Delta X_{rs} \geq ULN$ at baseline. Significant differences were found in both time to first exacerbation ($P=0.009$) and in time to first hospitalization ($P=0.017$; Figure 3A). Median time to first moderate or severe exacerbation was 76 weeks in patients with COPD with normal $\Delta X_{rs}$, compared with only 55 weeks in COPD patients with $\Delta X_{rs} \geq ULN$ at baseline (Table 4). The time until 25% of the patients were hospitalized was 126 weeks in patients with normal $\Delta X_{rs}$ and 72 weeks in patients with $\Delta X_{rs} \geq ULN$.

Mortality

At the 5-year census, 72 (17%) of the 425 patients with COPD had died. Deaths were significantly more frequent in patients with $\geq ULN$ than in patients with normal $\Delta X_{rs}$, but not significantly different between the $\geq ULN$ and the $EFL_{r_7}$ groups (Table 1). Mortality was higher in patients with $FEV_1 <50\%$ (Figure 4). The difference in mortality between patients with $\Delta X_{rs}$ in the normal range and $\geq ULN$ was driven by increased mortality in patients with $FEV_1 >50\%$ (Figure 4). Mortality was 17% in $\Delta X_{rs} \geq ULN$ patients with $FEV_1 >50\%$, compared to 5% in patients with normal $\Delta X_{rs}$ ($P<0.001$; Figure 4). Mortality in patients with $\Delta X_{rs} \geq ULN$ was similar to what was found in patients with COPD with much more advanced airway obstruction.

Discussion

Using data from the ECLIPSE study, we investigated associations between increased $\Delta X_{rs}$ at the ULN and at the threshold of $EFL_{r_7}$ with decline in 6MWD, risk of later exacerbations, and all-cause mortality. No change in 6MWD was found in patients with COPD with $\Delta X_{rs}$ in the normal range. All patients with COPD with $\Delta X_{rs} \geq ULN$ deteriorated significantly in 6MWD. Patients with COPD with $\Delta X_{rs} \geq ULN$ had increased risk for both moderate and severe exacerbations, and, in the patients with only moderate airway obstruction, $FEV_1 >50\%$, a significantly higher mortality. This study...
demonstrates that $\Delta X_{rs}$ provides valuable extra information in addition to FEV$_1$ when characterizing the effects of small-airway obstruction on key COPD outcomes.

We defined the ULN at the 97.5th percentile of healthy controls included in our study. Data describing the control group have previously been published.$^{13,18}$ The FOT threshold identifying a single flow-limited breath has been defined when within-breath reactance was $\Delta X_{rs} = 0.28$ kPa·s·L$^{-1}$. We interpreted our continuous spectrum measurements performed over several breaths as showing evidence of flow limitation when measurements between the ULN and the threshold for tidal expiratory flow limitation (EFL$^T$) were found. These borderline measurements are thought to represent a mixture of normal and flow-limited breaths.

Exercise limitation is extremely common in COPD, and even small decreases in the 6MWD over time identify patients with increased risks of dying.$^{27}$ When EFL$^T$ is present, patients can only increase their minute ventilation during exercise by increasing breathing frequency or by dynamic hyperinflation, allowing end-expiratory lung volume to rise.$^{28}$ Dynamic hyperinflation can be induced by self-paced walking exercise. This is usually assessed by changes in
operating lung volume.\textsuperscript{12,29} We did not measure lung volume during the 6MWT, but reasoned that patients with COPD showing evidence of flow limitation at baseline, either as having \( \Delta X_{\text{rs}} \geq \text{ULN} \) or the threshold of \( EFL_{\tau} \), were more likely to have a worse exercise tolerance at the same visit. This was true on a group level. The \( EFL_{\tau} \) group had the lowest 6MWD, but neither \( FEV_1 \) % predicted nor any cut-off level of \( \Delta X_{\text{rs}} \) could identify patients with COPD with a short walking distance (<350 m), as proposed by Spruit et al.\textsuperscript{10} No significant decline was seen in patients with \( \Delta X_{\text{rs}} \) in the normal range; in patients with COPD with \( \Delta X_{\text{rs}} \geq \text{ULN} \), it declined 37 m, and in patients with \( EFL_{\tau} \), it declined by 63 m. The minimal clinically important difference on an individual level has been suggested to be 30 m in an ERS/ATS systematic review;\textsuperscript{31} consequently, the differences seen over time between our subgroups defined by \( \Delta X_{\text{rs}} \geq \text{ULN} \) and \( EFL_{\tau} \) are likely to be clinically important.

Exacerbation and hospitalization rates at our site were similar to those reported in the completed ECLIPSE study and in the TORCH study.\textsuperscript{32,33} By negative binomial regression, the \( \Delta X_{\text{rs}} \) cut-offs \( \geq \text{ULN} \) and \( EFL_{\tau} \) were both significant predictors for higher rates of exacerbations with very similar RR, demonstrating that the increased risk of exacerbations by \( EFL_{\tau} \) is identified already at ULN. In the time to first event analysis of patients with \( \Delta X_{\text{rs}} \geq \text{ULN} \), we found a shorter time to first exacerbation and a shorter time to first hospitalization than that of the COPD patients with \( \Delta X_{\text{rs}} \) in the normal range. A previous study on hospitalized patients showed that many, but not all, have FOT-defined \( EFL_{\tau} \) during a COPD exacerbation.\textsuperscript{17} FOT measurements performed during hospitalized COPD exacerbations show that \( \Delta X_{\text{rs}} \) measurements improve during resolution of an exacerbation, although many patients remain \( EFL_{\tau} \) at discharge.\textsuperscript{17} At present, there is a shortage of readily measurable biomarkers that can predict the risk of future exacerbations. Our data suggest that, after adjusting for lung function and exacerbation history, \( EFL_{\tau} \) measurement can identify patients who are more likely to develop exacerbations. Further prospective studies to confirm these observations and explore their mechanism are merited.

Patients with COPD with an \( FEV_1 \) >50\% predicted and evidence of \( EFL_{\tau} \), defined as baseline \( \Delta X_{\text{rs}} \geq \text{ULN} \), had significantly higher risk of dying within the 5-year follow-up. Similar associations were not found in the patients with more advanced

| Table 3 Annual rate ratios estimated by negative binomial regression (N=395) |
|-----------------|-----------------|-----------------|-----------------|
| Baseline explanatory variables | RR  | 95% CI | P-value |
| \( \Delta X_{\text{rs}} \) | | | |
| \( \geq \text{ULN} \) (0.09 kPa s L\(^{-1}\)) and \( <EFL_{\tau} \) | 1.28 | 1.05, 1.55 | 0.011 |
| \( \geq EFL_{\tau} \) (0.28 kPa s L\(^{-1}\)) | 1.30 | 1.05, 1.64 | 0.009 |
| \( FEV_1 \) % predicted | 0.07 | 0.04, 0.14 | <0.001 |
| Age in decades | 1.36 | 1.06, 1.34 | 0.009 |
| Sex (male) | 0.85 | 0.72, 1.00 | 0.048 |
| Exacerbation in the year prior to inclusion | \( \geq 2 \) | 1.99 | 1.64, 2.41 | <0.001 |
| Intercept | 0.98 | 0.42, 2.27 | 0.965 |

Abbreviations: RR, estimated rate ratio; 95% CI, confidence interval; ULN, upper limit of normal 0.09 kPa s L\(^{-1}\); EFL, tidal expiratory flow limitation; \( FEV_1 \), forced expiratory volume in 1 second; \( FEV_1 \) %, percentage of predicted.

Figure 3 Time to first moderate or severe exacerbation (A) and to the first hospitalization (B) in COPD patients with \( \Delta X_{\text{rs}} \) measurements above the upper limit of normal (ULN), 0.9 kPa s L\(^{-1}\) (solid line), and below the ULN at the baseline visit. Dashed line at 25%.

A

B

\( \Delta X_{\text{rs}} \geq \text{ULN} \) No Yes

\( \Delta X_{\text{rs}} \geq \text{ULN} \) No Yes

\( \Delta X_{\text{rs}} \geq \text{ULN} \) No Yes

\( \Delta X_{\text{rs}} \geq \text{ULN} \) No Yes
Table 4  Exacerbations, hospitalizations, and deaths in COPD patients with and without ∆Xrs ≥ ULN at baseline (N=425)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>∆Xrs &lt; ULN</th>
<th>∆Xrs ≥ ULN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total N</td>
<td>213</td>
<td>212</td>
</tr>
<tr>
<td>N patients (%) with exacerbation</td>
<td>144 (68%)</td>
<td>152 (72%)</td>
</tr>
<tr>
<td>Median time (weeks) to first exacerbation (95% CI)</td>
<td>76 (57, 95)</td>
<td>55 (42, 68)</td>
</tr>
<tr>
<td>Log-rank test</td>
<td>P=0.009</td>
<td></td>
</tr>
<tr>
<td>N patients (%) hospitalized</td>
<td>62 (29%)</td>
<td>84 (40%)</td>
</tr>
<tr>
<td>Time (weeks) until 25% of the patients were hospitalized</td>
<td>126</td>
<td>72</td>
</tr>
<tr>
<td>Log-rank test</td>
<td>P=0.017</td>
<td></td>
</tr>
<tr>
<td>N dead at 5-year follow-up</td>
<td>25 (12%)</td>
<td>46 (22%)</td>
</tr>
<tr>
<td>Log-rank test</td>
<td>P=0.011</td>
<td></td>
</tr>
</tbody>
</table>

Note: ULN defined at ∆Xrs ≥ 0.09 kPa s L⁻¹.  
Abbreviations: ULN, upper limit of normal 0.09 kPa s L⁻¹; 95% CI, 95% confidence interval.

airway obstruction and FEV₁ <50%. However, COPD is a complex, heterogeneous disease, and respiratory impairment is associated with higher incidence of comorbidities, such as hypertension, cardiovascular disease, and diabetes. If there is an association between ∆Xrs and mortality, the higher risk of adverse outcomes associated with comorbid disease could mask such an association with advanced disease. Although the association between death and ∆Xrs was highly significant, this sub-analysis should be interpreted with caution due to the relatively small number of deaths in patients with FEV₁ >50% predicted (Table 1).

There are certain limitations of this study. The FOT threshold identifying a single flow-limited breath has been defined at ∆Xrs >0.28 kPa s L⁻¹. It is not known whether the use of this threshold may lead to different results when applied to values measured over a continuous spectrum of several breaths. Previously published data show that the end-expiratory lung volume varies from breath-to-breath, affecting the prevalence of EFL<sub>T</sub>. Although the prevalence of EFL<sub>T</sub> increased as the FEV₁ % predicted declined, not all patients with very severe airway obstruction were found to have EFL<sub>T</sub>. In previous studies on elderly and COPD with the NEP technique, higher prevalence of EFL<sub>T</sub> have been reported than in the present study. Different inclusion criteria and differences in sensitivity between the NEP and the FOT technique, together with the possibility that in borderline patients the application of a NEP per se could lead to development of EFL<sub>T</sub>, are likely explanations. The wide reference range of FEV₁ inevitably may also lead to an overestimation of the suspected lung function decline in many patients.

As previously noted, EFL<sub>T</sub> varies between breaths in many patients with COPD and varies with repeat testing, likely reflecting differences in the end-expiratory lung volume on different test days. Physiological variability in these measurements might require the repetition of this test in different periods to increase the sensitivity of our test. Despite this limitation, important relationships related to the presence of tidal flow limitation were seen, even when the data were controlled for severity of airflow obstruction measured by FEV₁. The data reflect results from the largest recruiting center in the ECLIPSE study, in which patients were carefully characterized using standardized methodologies including oscillatory mechanics.

Conclusion  
Consistent differences in clinically relevant outcomes were found, such as exercise capability, exacerbations, hospitalizations, and death in COPD patients with baseline ∆Xrs beyond the ULN. This is below the established threshold for EFL<sub>T</sub>. Our data support previous studies showing that patients with EFL<sub>T</sub> have worse lung mechanics than is evident from FEV₁ measurement alone. The present study suggests that evidence of EFL<sub>T</sub>, measured during tidal breathing in an effort-independent fashion, can identify a subgroup of COPD patients with worse clinical outcomes.

Acknowledgments  
The study was sponsored by GlaxoSmithKline. The sponsor had no role in the design of the study, collection and analysis of the data, nor in the preparation of the manuscript.
The work was performed at Haukeland University Hospital. The authors thank all participants who took part in the study, all members of the Bergen Respiratory Research Group who contributed to the data collection, and offer special thanks to Lene Svendsen, Rita Oppedal, Tina Endresen-Vinsjøvik, and Eli Nordeide who performed/supervised the pulmonary function tests.

Author contributions
The corresponding author BBA wrote the manuscript, had access to all of the data in the study, and takes responsibility for the integrity of the data and the accuracy of the data analysis. PMAC was in the ECLIPSE Scientific Committee and PSB in the ECLIPSE Steering Committee. They both contributed to the development of the research design. PSB, JAH, and TMLE also contributed in the data collection. All authors, including RLJ and RD, contributed to the data analysis, the clinical interpretation of the data, and to reviewing the final submission.

Disclosure
The authors report no conflicts of interest in this work.

References


## Supplementary materials

**Figure S1** Scatterplot of ΔXrs plotted against FEV₁ (%) predicted in healthy controls (N=229). Mean represented by the solid line. The dashed line represents the 97.5th percentile, the upper limit of normal (ULN).

### Table S1 Baseline characteristics in men and women (N=425)

<table>
<thead>
<tr>
<th>Subject characteristics</th>
<th>Total</th>
<th>Men</th>
<th>Women</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects (n)</td>
<td>425</td>
<td>254</td>
<td>171</td>
<td>0.014</td>
</tr>
<tr>
<td>Age (years)</td>
<td>63 (7)</td>
<td>64 (7)</td>
<td>62 (7)</td>
<td></td>
</tr>
<tr>
<td>BMI kg/m²</td>
<td>25 (5)</td>
<td>26 (5)</td>
<td>25 (6)</td>
<td>ns</td>
</tr>
<tr>
<td>Pack-years (years)</td>
<td>41 (23)</td>
<td>45 (24)</td>
<td>33 (18)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>mMRC</td>
<td>1.6 (1, 2)</td>
<td>1.6 (1, 2)</td>
<td>1.7 (1, 2)</td>
<td>ns</td>
</tr>
<tr>
<td>FEV₁ (L)</td>
<td>1.5 (0.5)</td>
<td>1.6 (0.6)</td>
<td>1.3 (0.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEV₁ (%)</td>
<td>46 (14)</td>
<td>45 (14)</td>
<td>48 (13)</td>
<td>0.007</td>
</tr>
<tr>
<td>FVC (L)</td>
<td>3.3 (0.9)</td>
<td>3.7 (0.8)</td>
<td>2.6 (0.6)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>∆Xrs (kPa.s.L⁻¹)</td>
<td>0.14 (0.17)</td>
<td>0.13 (0.14)</td>
<td>0.16 (0.20)</td>
<td>ns</td>
</tr>
</tbody>
</table>

**Note:** Data presented as mean (standard deviation) unless otherwise stated.

**Abbreviations:** ULN, upper limit of normal 0.09 kPa.s.L⁻¹; EFL, tidal expiratory flow limitation; BMI, body mass index; Pack-years, packs of 20 cigarettes smoked per day × years as a smoker; Frequent exacerbators, percentage with ≥2 exacerbations the year prior to inclusion; mMRC, modified Medical Research Council dyspnea scale score – mean (quartiles); FEV₁, forced expiratory volume in 1 second; FEV₁ (%), FEV₁ percentage of predicted; FVC, forced vital capacity; IC, inspiratory capacity; IC (%), IC percentage of predicted; ∆Xrs, difference between mean inspiratory and mean expiratory reactance at 5 Hz over multiple breaths; 6MWD, 6-minute walk distance.

---

**International Journal of COPD**

**Publish your work in this journal**

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols.

**Submit your manuscript here:** [http://www.dovepress.com/submit-manuscript.php](http://www.dovepress.com/submit-manuscript.php)